{"title_page": "Diabetic nephropathy", "text_new": "{{short description|Chronic loss of kidney function}}\n{{Infobox medical condition (new)\n| name            = Diabetic nephropathy\n| synonyms        = Diabetic kidney disease\n| image           = Nodular_glomerulosclerosis.jpeg\n| caption         = Two glomeruli in diabetic nephropathy: the acellular light purple areas within the capillary tufts are the destructive mesangial matrix deposits.\n| pronounce       = \n| field           = \n| symptoms        = Tiredness<ref name=nih/>\n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = High blood pressure, Unstable blood glucose<ref name=nih/>\n| diagnosis       = Abnormal levels of urinary albumin<ref name=lewis2014/>\n| differential    = \n| prevention      = \n| treatment       = ACE inhibitors<ref name=ace/>\n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n<!-- Definition and symptoms -->\n'''Diabetic nephropathy''' ('''DN'''), also known as '''diabetic kidney disease''',<ref>{{cite book | title = Nutrition Therapy for Chronic Kidney Disease |  chapter = Diabetes Management | vauthors = Kittell F | veditors = Thomas LK, Othersen JB | year = 2012 | publisher = CRC Press | page = 198 | chapter-url = https://books.google.com/books?id=DreAtq_hKmcC&pg=PA198}}</ref> is the chronic loss of [[kidney function]] occurring in those with [[diabetes mellitus]]. [[Proteinuria|Protein loss in the urine]] due to damage to the [[glomerulus|glomeruli]] may become massive, and cause a low [[serum albumin]] with resulting [[Anasarca|generalized body swelling (edema)]] and result in the [[nephrotic syndrome]]. Likewise, the estimated [[glomerular filtration rate]] (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m<sup>2</sup></small>  to less than 15, at which point the patient is said to have [[end-stage kidney disease]] (ESKD).<ref>{{cite book | first1 = Dan | last1 = Longo | first2 = Anthony | last2 = Fauci | first3 =  Dennis | last3= Kasper | first4 = Stephen | last4 = Hauser | first5 = J. | last5 = Jameson | first6 = Joseph | last6 = Loscalzo | name-list-format = vanc | title = Harrison's manual of medicine|date=2013|publisher=McGraw-Hill Medical|location=New York|isbn=978-0-07-174519-2|edition=18th | page = 2982 }}</ref> It usually is slowly progressive over years.<ref>{{cite journal | vauthors = Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH | title = Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988\u20132014 | journal = JAMA | volume = 316 | issue = 6 | pages = 602\u201310 | date = August 2016 | pmid = 27532915 | pmc = 5444809 | doi = 10.1001/jama.2016.10924 }}</ref>\n\n<!-- Cause and Pathophysiology -->\nPathophysiologic abnormalities in '''DM''' begin with long-standing poorly controlled blood glucose levels. This is followed by multiple changes in the filtration units of the kidneys, the [[nephron]]s. (There are normally about 750,000\u20131.5 million nephrons in each adult kidney).<ref>{{cite book | first1 = John | last1 = Hall | first2 = Arthur | last2 = Guyton | name-list-format = vanc |title= Textbook of Medical Physiology | date = 2005 | publisher = W.B. Saunders | location  =Philadelphia | isbn = 978-0-7216-0240-0 | edition = 11th | page = 310 }}</ref> Initially, there is constriction of the [[efferent arterioles]] and dilation of [[afferent arterioles]], with resulting glomerular capillary hypertension and hyperfiltration; this gradually changes to hypofiltration over time.<ref>{{cite web | title = diabetic nephropathy | url = http://medical-dictionary.thefreedictionary.com/diabetic+nephropathy | access-date = 2015-06-27 }}</ref> Concurrently, there are changes within the glomerulus itself: these include a thickening of the [[basement membrane]], a widening of the slit membranes of the [[podocytes]], an increase in the number of mesangial cells, and an increase in mesangial matrix. This matrix invades the glomerular capillaries and produces deposits called Kimmelstiel-Wilson nodules. The mesangial cells and matrix can progressively expand and consume the entire glomerulus, shutting off filtration.<ref name=\"Schl\u00f6ndorff_2009\">{{cite journal | vauthors = Schl\u00f6ndorff D, Banas B | title = The mesangial cell revisited: no cell is an island | journal = Journal of the American Society of Nephrology | volume = 20 | issue = 6 | pages = 1179\u201387 | date = June 2009 | pmid = 19470685 | doi = 10.1681/ASN.2008050549 | doi-access = free }}</ref>\n\n<!-- Prevention and Treatment -->\nThe status of DN may be monitored by measuring two values: the amount of protein in the urine - [[proteinuria]]; and a blood test called the serum [[creatinine]]. The amount of the proteinuria reflects the degree of damage to any still-functioning glomeruli. The value of the [[serum creatinine]] can be used to calculate the [[estimated glomerular filtration rate]] (eGFR), which reflects the percentage of glomeruli which are no longer filtering the blood. {{citation needed|date=December 2017}} Treatment with an [[angiotensin converting enzyme inhibitor]] (ACEI) or [[angiotensin receptor blocker]] (ARB), which dilates the [[arteriole]] exiting the glomerulus, thus reducing the [[blood pressure]] within the glomerular capillaries, which may slow (but not stop) progression of the disease. Three classes of diabetes medications \u2013 [[GLP-1 agonist]]s, [[DPP-4 inhibitor]]s, and [[SGLT2 inhibitor]]s \u2013 are also thought to slow the progression of diabetic nephropathy.<ref>{{cite journal | vauthors = de Boer IH | title = A New Chapter for Diabetic Kidney Disease | journal = The New England Journal of Medicine | volume = 377 | issue = 9 | pages = 885\u2013887 | date = August 2017 | pmid = 28854097 | doi = 10.1056/nejme1708949 }}</ref>\n\n<!-- Epidemiology -->\nDiabetic nephropathy is the most common cause of ESKD and is a serious complication that affects approximately one quarter of adults with diabetes in the United States.<ref name=\"Fernandez2014\">{{cite journal | vauthors = Mora-Fern\u00e1ndez C, Dom\u00ednguez-Pimentel V, de Fuentes MM, G\u00f3rriz JL, Mart\u00ednez-Castelao A, Navarro-Gonz\u00e1lez JF | title = Diabetic kidney disease: from physiology to therapeutics | journal = The Journal of Physiology | volume = 592 | issue = 18 | pages = 3997\u20134012 | date = September 2014 | pmid = 24907306 | pmc = 4198010 | doi = 10.1113/jphysiol.2014.272328 }}</ref><ref name=\"Ding2015\">{{cite journal | vauthors = Ding Y, Choi ME | title = Autophagy in diabetic nephropathy | journal = The Journal of Endocrinology | volume = 224 | issue = 1 | pages = R15\u201330 | date = January 2015 | pmid = 25349246 | pmc = 4238413 | doi = 10.1530/JOE-14-0437 }}</ref> Affected individuals with end-stage kidney disease often require [[hemodialysis]] and eventually [[kidney transplantation]] to replace the failed kidney function.<ref name=\"ReferenceB\">{{cite journal | vauthors = Lizicarova D, Krahulec B, Hirnerova E, Gaspar L, Celecova Z | title = Risk factors in diabetic nephropathy progression at present | journal = Bratislavske Lekarske Listy | volume = 115 | issue = 8 | pages = 517\u201321 | year = 2014 | pmid = 25246291 | doi = 10.4149/BLL_2014_101 | doi-access = free }}</ref> Diabetic nephropathy is associated with an increased [[Mortality rate|risk of death]] in general, particularly from [[cardiovascular disease]].<ref name=\"Fernandez2014\"/><ref name=\"P\u00e1lsson R 2014\">{{cite journal | vauthors = P\u00e1lsson R, Patel UD | title = Cardiovascular complications of diabetic kidney disease | journal = Advances in Chronic Kidney Disease | volume = 21 | issue = 3 | pages = 273\u201380 | date = May 2014 | pmid = 24780455 | pmc = 4045477 | doi = 10.1053/j.ackd.2014.03.003 }}</ref>\n\n==Signs and symptoms==\nThe onset of symptoms is 5 to 10 years after the disease begins.<ref name=\"nih\" />  A usual first symptom is frequent urination at night: [[nocturia]]. Other symptoms include [[tiredness]], [[headache]]s, a [[malaise|general feeling of illness]], [[nausea]], [[vomiting]], frequent daytime urination, [[Anorexia (symptom)|lack of appetite]], [[Pruritus|itchy skin]], and [[edema|leg swelling]].<ref name=\"nih\" />\n\n==Risk factors==\nThe incidence of diabetic nephropathy is higher in people with diabetes that have one or more of the following conditions:<ref name=\"nih\">{{Cite web|title = Diabetes and kidney disease: MedlinePlus Medical Encyclopedia|url = https://www.nlm.nih.gov/medlineplus/ency/article/000494.htm|website = www.nlm.nih.gov|access-date = 2015-06-27}}</ref>\n* Poor control of blood glucose\n* Uncontrolled [[Hypertension|high blood pressure]]\n* [[Type 1 diabetes mellitus]], with onset before age 20\n* Past or current [[Tobacco smoking|cigarette use]]\n* A family history of diabetic nephropathy\n\n==Pathophysiology==\n[[File:Physiology of Nephron.png|250px|thumb|right|Diagram showing the basic outline of nephron structure and function: diabetic nephropathy is associated with changes in the afferent and efferent arterioles, causing capillary hypertension; and damage to the glomerular capillaries of multiple causes, including mesangial matrix deposition]] \nThe pathophysiology of the glomerulus in DN can best be understood by considering the three involved cells as a unit: the [[endothelial cell]], the [[podocyte]], and the [[mesangial cell]]. These cells are in physical contact with one another at various locations within the glomerulus; they also communicate with one another chemically at a distance. All three cells are abnormal in DN.<ref name=\"Schl\u00f6ndorff_2009\"/>\n\n[[Diabetes]] causes a number of changes to the body's [[metabolism]] and [[Hemodynamics|blood circulation]], which likely combine to produce excess [[reactive oxygen species]] (chemically reactive molecules containing oxygen). These changes damage the kidney's [[Glomerulus (kidney)|glomeruli]] (networks of [[Capillary|tiny blood vessels]]), which leads to the hallmark feature of [[albumin]] in the urine (called [[albuminuria]]).<ref>{{cite journal | vauthors = Cao Z, Cooper ME | title = Pathogenesis of diabetic nephropathy | journal = Journal of Diabetes Investigation | volume = 2 | issue = 4 | pages = 243\u20137 | date = August 2011 | pmid = 24843491 | pmc = 4014960 | doi = 10.1111/j.2040-1124.2011.00131.x }}</ref> As diabetic nephropathy progresses, a structure in the glomeruli known as the glomerular filtration barrier (GFB) is increasingly damaged.<ref name=\"Fernandez2014\"/> This barrier is composed of three layers including the fenestrated [[endothelium]], the [[glomerular basement membrane]], and the [[epithelium|epithelial]] [[podocyte]]s.<ref name=\"Fernandez2014\"/> The GFB is responsible for the highly selective filtration of blood entering the kidney's glomeruli and normally only allows the passage of water, small molecules, and very small proteins (albumin does not pass through the intact GFB).<ref name=\"Fernandez2014\"/> Damage to the glomerular basement membrane allows proteins in the blood to leak through, leading to proteinuria. Deposition of abnormally large amounts of mesangial matrix causes [[Periodic acid\u2013Schiff stain|periodic-acid schiff]] positive nodules called Kimmelstiel\u2013Wilson nodules.<ref>{{cite journal|author=Kimmelstiel, Paul|authorlink=Paul Kimmelstiel|author2=Wilson, Clifford|authorlink2=Clifford Wilson|title=Intercapillary lesions in the glomeruli of the kidney|journal=The American Journal of Pathology|volume=12|issue=1|year=1936|pages=83\u201398.7|pmc=1911022|pmid=19970254}}</ref>\n\n[[Hyperglycemia|High blood sugar]], which leads to formation of [[advanced glycation end product]]s;  and [[cytokine]]s have also been implicated as mechanisms for the development of diabetic nephropathy.<ref>{{Cite journal|title = Diabetic Nephropathy: Background, Pathophysiology, Etiology|url = http://emedicine.medscape.com/article/238946-overview#a4|date = 2015-06-20}}</ref>\n\n==Diagnosis==\n[[File:Ultrasonography of kidney with diabetic nephropathy - annotated.jpg|thumb|left|[[Medical ultrasonography|Ultrasonography]] showing [[Echogenicity|hyperechogenicity]] of the [[renal cortex]], visualized in the image as brighter than the liver.]]\n{| class=\"wikitable\" style=\"float:right; margin-left:5px\"\nDiagnosis is based on the measurement of abnormal levels of urinary albumin in a diabetic<ref name=\"lewis2014\">{{cite journal | vauthors = Lewis G, Maxwell AP | title = Risk factor control is key in diabetic nephropathy | journal = The Practitioner | volume = 258 | issue = 1768 | pages = 13\u20137, 2 | date = February 2014 | pmid = 24689163 }}</ref>  coupled with exclusion of other causes of albuminuria.\nAlbumin measurements are defined as follows:<ref>{{Cite web|title = CDC \u2013 Chronic Kidney Disease \u2013 Glossary|url = http://nccd.cdc.gov/ckd/help.aspx?section=G|access-date = 2015-07-02}}</ref> \n:::::::::::* Normal [[albuminuria]]: urinary albumin excretion <30&nbsp;mg/24h;\n:::::::::::* [[Microalbuminuria]]: urinary albumin excretion in the range of 30\u2013299&nbsp;mg/24h;\n:::::::::::* [[Macroalbuminuria]]: urinary albumin excretion \u2265300&nbsp;mg/24h.\nIt is recommended that diabetics have their albumin levels checked annually, beginning immediately after a diagnosis of type 2 diabetes and five years after a diagnosis of type 1 diabetes.<ref name=\"lewis2014\" /><ref>{{cite journal | vauthors = Koroshi A | title = Microalbuminuria, is it so important? | journal = Hippokratia | volume = 11 | issue = 3 | pages = 105\u20137 | date = July 2007 | pmid = 19582202 | pmc = 2658722 }}</ref>\n\n[[Medical imaging]] of the kidneys, generally by [[medical ultrasonography|ultrasonography]], is recommended as part of a [[differential diagnosis]] if there is suspicion of [[urinary tract obstruction]], [[urinary tract infection]], or [[kidney stone]]s or [[polycystic kidney disease]].<ref name=\"Grossde Azevedo2004\">{{cite journal | vauthors = Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T | title = Diabetic nephropathy: diagnosis, prevention, and treatment | journal = Diabetes Care | volume = 28 | issue = 1 | pages = 164\u201376 | date = January 2005 | pmid = 15616252 | doi = 10.2337/diacare.28.1.164 }}</ref>\n\n!CKD Stage<ref name=\"pmid22439155\">{{cite book | vauthors = Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ | display-authors = 6 | title = Chronic Kidney Disease Stages 1\u20133: Screening, Monitoring, and Treatment [Internet] | pmid = 22439155 | doi = | url = https://www.ncbi.nlm.nih.gov/books/NBK84558/ | publisher = Agency for Healthcare Research and Quality (US) | date = January 2012 }}</ref>\n\n!eGFR level <small>(mL/min/1.73 m<sup>2</sup>)</small>\n|-\n|Stage 1\n|style=\"text-align:center\"|\u2265 90\n|-\n|Stage 2\n|style=\"text-align:center\"|60\u201389\n|-\n|Stage 3\n|style=\"text-align:center\"|30\u201359\n|-\n|Stage 4\n|style=\"text-align:center\"|15\u201329\n|-\n|Stage 5\n|style=\"text-align:center\"|< 15\n|}\n===Staging===\nTo stage the degree of damage in this (and any) kidney disease, the serum creatinine is determined and used to calculate the estimated glomerular filtration rate ([[Estimated Glomerular Filtration Rate|eGFR]]). Normal eGFR is equal to or greater than 90ml/min/1.73 m<sup>2</sup>.<ref>{{Cite web|title = Glomerular filtration rate: MedlinePlus Medical Encyclopedia|url =  https://www.nlm.nih.gov/medlineplus/ency/article/007305.htm|website = www.nlm.nih.gov|access-date = 2015-07-02}}</ref>\n<br>\n<br>\n\n== Treatment ==\nThe goals of treatment are to slow the progression of kidney damage and control related complications. The main treatment, once proteinuria is established, is [[ACE inhibitor]] medications, which usually reduce proteinuria levels and slow the progression of diabetic nephropathy.<ref name=\"ace\">{{cite journal | vauthors = Lim AK | title = Diabetic nephropathy \u2013 complications and treatment | journal = [[International Journal of Nephrology and Renovascular Disease]] | volume = 7 | pages = 361\u201381 | date = 2014 | pmid = 25342915 | pmc = 4206379 | doi = 10.2147/IJNRD.S40172 }}</ref> Other issues that are important in the management of this condition include control of [[high blood pressure]] and [[blood sugar]] levels (see [[diabetes management]]), as well as the reduction of dietary salt intake.<ref>{{Cite journal|title = Diabetic Nephropathy Treatment & Management: Approach Considerations, Glycemic Control, Management of Hypertension|url = http://emedicine.medscape.com/article/238946-treatment|date = 2015-06-20}}</ref>\n\n==Prognosis==\nDiabetic nephropathy in type 2 diabetes can be more difficult to predict because the onset of diabetes is not usually well established. Without intervention, 20\u201340 percent of patients with type 2 diabetes/microalbuminuria, will evolve to macroalbuminuria.<ref>{{Cite journal|title = Clinical Evidence Handbook: Diabetic Nephropathy: Preventing Progression \u2013 American Family Physician|issue = 6|pages = 732|url = http://www.aafp.org/afp/2011/0315/p732.html|journal = American Family Physician|volume = 83|access-date = 2015-06-27|first = Michael|last = Shlipak | name-list-format = vanc |date = 2011-03-15}}</ref>\n\nDiabetic nephropathy is the most common cause of [[end-stage kidney disease]],<ref name=\"Fernandez2014\"/><ref name=\"Ding2015\"/> which may require [[hemodialysis]] or even [[kidney transplantation]].<ref name=\"ReferenceB\"/> It is associated with an increased [[Mortality rate|risk of death]] in general, particularly from [[cardiovascular disease]].<ref name=\"Fernandez2014\"/><ref name=\"P\u00e1lsson R 2014\"/>\n\n== Epidemiology ==\nIn the U.S., diabetic nephropathy affected an estimated 6.9 million people during 2005\u20132008.<ref>{{Cite book|title = Diabetes and Kidney Disease|url = https://books.google.com/books?id=wsYkBAAAQBAJ&pg=PA10&dq=Diabetic+nephropathy+epidemiology |publisher = Springer|date = 2014-01-01|isbn = 9781493907939 |first = Edgar V.|last = Lerma | name-list-format = vanc }}</ref> The number of people with diabetes and consequently diabetic nephropathy is expected to rise substantially by the year 2050.<ref>{{Cite book|title = Diabetes and the Kidney|url = https://books.google.com/books?id=XZk7AQAAQBAJ&pg=PA1&dq=Diabetic+nephropathy+epidemiology |publisher = Karger Medical and Scientific Publishers|date = 2011-06-08|isbn = 9783805597432 | vauthors = Lai KN, Tang SC }}</ref>\n\n== See also ==\n* [[Diabetic diet]]\n* [[Hyperbaric medicine]]\n* [[Nephrology]]\n\n== References ==\n{{Reflist|32em}}\n\n== Further reading ==\n{{refbegin|32em}}\n*{{Cite web|title = Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis|url = http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?AccessionNumber=12009100199#.VZXF8TfbJpg|website = www.crd.york.ac.uk|access-date = 2015-07-02}}\n* {{cite journal | vauthors = Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T | title = Diabetic nephropathy: diagnosis, prevention, and treatment | journal = Diabetes Care | volume = 28 | issue = 1 | pages = 164\u201376 | date = January 2005 | pmid = 15616252 | doi = 10.2337/diacare.28.1.164 }}\n* {{cite journal | vauthors = Tziomalos K, Athyros VG | title = Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis | journal = The Review of Diabetic Studies | volume = 12 | issue = 1\u20132 | pages = 110\u20138 | year = 2015 | pmid = 26676664 | pmc = 5397986 | doi = 10.1900/RDS.2015.12.110 }}\n* {{cite journal | vauthors = Kume S, Koya D, Uzu T, Maegawa H | title = Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy | journal = BioMed Research International | volume = 2014 | pages = 315494 | date = 2014 | pmid = 25126552 | pmc = 4122096 | doi = 10.1155/2014/315494 }}\n* {{cite journal | vauthors = Doshi SM, Friedman AN | title = Diagnosis and Management of Type 2 Diabetic Kidney Disease | journal = Clinical Journal of the American Society of Nephrology | volume = 12 | issue = 8 | pages = 1366\u20131373 | date = August 2017 | pmid = 28280116 | pmc = 5544517 | doi = 10.2215/CJN.11111016  }}\n{{refend}}\n\n== External links ==\n{{Medical resources\n|  DiseasesDB      =  \n|  ICD10           = E10.2, E11.2, E12.2, E13.2, E14.2\n|  ICD9            = {{ICD9|250.4}}\n|  ICDO            =  \n|  OMIM            =  \n|  MedlinePlus     = 000494 \n|  eMedicineSubj   =  \n|  eMedicineTopic  =  \n|  MeshID          = D003928 \n}}\n{{Scholia|topic}}\n{{Nephrology}}\n{{Endocrine pathology}}\n{{Diabetes}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Diabetic Nephropathy}}\n[[Category:Kidney diseases]]\n[[Category:Vascular diseases]]\n[[Category:Diabetes]]\n", "text_old": "{{short description|Chronic loss of kidney function}}\n{{Infobox medical condition (new)\n| name            = Diabetic nephropathy\n| synonyms        = Diabetic kidney disease\n| image           = Nodular_glomerulosclerosis.jpeg\n| caption         = Two glomeruli in diabetic nephropathy: the acellular light purple areas within the capillary tufts are the destructive mesangial matrix deposits.\n| pronounce       = \n| field           = \n| symptoms        = Tiredness<ref name=nih/>\n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = High blood pressure, Unstable blood glucose<ref name=nih/>\n| diagnosis       = Abnormal levels of urinary albumin<ref name=lewis2014/>\n| differential    = \n| prevention      = \n| treatment       = ACE inhibitors<ref name=ace/>\n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n<!-- Definition and symptoms -->\n'''Diabetic nephropathy''' ('''DN'''), also known as '''diabetic kidney disease''',<ref>{{cite book | title = Nutrition Therapy for Chronic Kidney Disease |  chapter = Diabetes Management | vauthors = Kittell F | veditors = Thomas LK, Othersen JB | year = 2012 | publisher = CRC Press | page = 198 | chapter-url = https://books.google.com/books?id=DreAtq_hKmcC&pg=PA198}}</ref> is the chronic loss of [[kidney function]] occurring in those with [[diabetes mellitus]]. [[Proteinuria|Protein loss in the urine]] due to damage to the [[glomerulus|glomeruli]] may become massive, and cause a low [[serum albumin]] with resulting [[Anasarca|generalized body swelling (edema)]] and result in the [[nephrotic syndrome]]. Likewise, the estimated [[glomerular filtration rate]] (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m<sup>2</sup></small>  to less than 15, at which point the patient is said to have [[end-stage kidney disease]] (ESKD).<ref>{{cite book | first1 = Dan | last1 = Longo | first2 = Anthony | last2 = Fauci | first3 =  Dennis | last3= Kasper | first4 = Stephen | last4 = Hauser | first5 = J. | last5 = Jameson | first6 = Joseph | last6 = Loscalzo | name-list-format = vanc | title = Harrison's manual of medicine|date=2013|publisher=McGraw-Hill Medical|location=New York|isbn=978-0-07-174519-2|edition=18th | page = 2982 }}</ref> It usually is slowly progressive over years.<ref>{{cite journal | vauthors = Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH | title = Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988\u20132014 | journal = JAMA | volume = 316 | issue = 6 | pages = 602\u201310 | date = August 2016 | pmid = 27532915 | pmc = 5444809 | doi = 10.1001/jama.2016.10924 }}</ref>\n\n<!-- Cause and Pathophysiology -->\nPathophysiologic abnormalities in DN begin with long-standing poorly controlled blood glucose levels. This is followed by multiple changes in the filtration units of the kidneys, the [[nephron]]s. (There are normally about 750,000\u20131.5 million nephrons in each adult kidney).<ref>{{cite book | first1 = John | last1 = Hall | first2 = Arthur | last2 = Guyton | name-list-format = vanc |title= Textbook of Medical Physiology | date = 2005 | publisher = W.B. Saunders | location  =Philadelphia | isbn = 978-0-7216-0240-0 | edition = 11th | page = 310 }}</ref> Initially, there is constriction of the [[efferent arterioles]] and dilation of [[afferent arterioles]], with resulting glomerular capillary hypertension and hyperfiltration; this gradually changes to hypofiltration over time.<ref>{{cite web | title = diabetic nephropathy | url = http://medical-dictionary.thefreedictionary.com/diabetic+nephropathy | access-date = 2015-06-27 }}</ref> Concurrently, there are changes within the glomerulus itself: these include a thickening of the [[basement membrane]], a widening of the slit membranes of the [[podocytes]], an increase in the number of mesangial cells, and an increase in mesangial matrix. This matrix invades the glomerular capillaries and produces deposits called Kimmelstiel-Wilson nodules. The mesangial cells and matrix can progressively expand and consume the entire glomerulus, shutting off filtration.<ref name=\"Schl\u00f6ndorff_2009\">{{cite journal | vauthors = Schl\u00f6ndorff D, Banas B | title = The mesangial cell revisited: no cell is an island | journal = Journal of the American Society of Nephrology | volume = 20 | issue = 6 | pages = 1179\u201387 | date = June 2009 | pmid = 19470685 | doi = 10.1681/ASN.2008050549 | doi-access = free }}</ref>\n\n<!-- Prevention and Treatment -->\nThe status of DN may be monitored by measuring two values: the amount of protein in the urine - [[proteinuria]]; and a blood test called the serum [[creatinine]]. The amount of the proteinuria reflects the degree of damage to any still-functioning glomeruli. The value of the [[serum creatinine]] can be used to calculate the [[estimated glomerular filtration rate]] (eGFR), which reflects the percentage of glomeruli which are no longer filtering the blood. {{citation needed|date=December 2017}} Treatment with an [[angiotensin converting enzyme inhibitor]] (ACEI) or [[angiotensin receptor blocker]] (ARB), which dilates the [[arteriole]] exiting the glomerulus, thus reducing the [[blood pressure]] within the glomerular capillaries, which may slow (but not stop) progression of the disease. Three classes of diabetes medications \u2013 [[GLP-1 agonist]]s, [[DPP-4 inhibitor]]s, and [[SGLT2 inhibitor]]s \u2013 are also thought to slow the progression of diabetic nephropathy.<ref>{{cite journal | vauthors = de Boer IH | title = A New Chapter for Diabetic Kidney Disease | journal = The New England Journal of Medicine | volume = 377 | issue = 9 | pages = 885\u2013887 | date = August 2017 | pmid = 28854097 | doi = 10.1056/nejme1708949 }}</ref>\n\n<!-- Epidemiology -->\nDiabetic nephropathy is the most common cause of ESKD and is a serious complication that affects approximately one quarter of adults with diabetes in the United States.<ref name=\"Fernandez2014\">{{cite journal | vauthors = Mora-Fern\u00e1ndez C, Dom\u00ednguez-Pimentel V, de Fuentes MM, G\u00f3rriz JL, Mart\u00ednez-Castelao A, Navarro-Gonz\u00e1lez JF | title = Diabetic kidney disease: from physiology to therapeutics | journal = The Journal of Physiology | volume = 592 | issue = 18 | pages = 3997\u20134012 | date = September 2014 | pmid = 24907306 | pmc = 4198010 | doi = 10.1113/jphysiol.2014.272328 }}</ref><ref name=\"Ding2015\">{{cite journal | vauthors = Ding Y, Choi ME | title = Autophagy in diabetic nephropathy | journal = The Journal of Endocrinology | volume = 224 | issue = 1 | pages = R15\u201330 | date = January 2015 | pmid = 25349246 | pmc = 4238413 | doi = 10.1530/JOE-14-0437 }}</ref> Affected individuals with end-stage kidney disease often require [[hemodialysis]] and eventually [[kidney transplantation]] to replace the failed kidney function.<ref name=\"ReferenceB\">{{cite journal | vauthors = Lizicarova D, Krahulec B, Hirnerova E, Gaspar L, Celecova Z | title = Risk factors in diabetic nephropathy progression at present | journal = Bratislavske Lekarske Listy | volume = 115 | issue = 8 | pages = 517\u201321 | year = 2014 | pmid = 25246291 | doi = 10.4149/BLL_2014_101 | doi-access = free }}</ref> Diabetic nephropathy is associated with an increased [[Mortality rate|risk of death]] in general, particularly from [[cardiovascular disease]].<ref name=\"Fernandez2014\"/><ref name=\"P\u00e1lsson R 2014\">{{cite journal | vauthors = P\u00e1lsson R, Patel UD | title = Cardiovascular complications of diabetic kidney disease | journal = Advances in Chronic Kidney Disease | volume = 21 | issue = 3 | pages = 273\u201380 | date = May 2014 | pmid = 24780455 | pmc = 4045477 | doi = 10.1053/j.ackd.2014.03.003 }}</ref>\n\n==Signs and symptoms==\nThe onset of symptoms is 5 to 10 years after the disease begins.<ref name=\"nih\" />  A usual first symptom is frequent urination at night: [[nocturia]]. Other symptoms include [[tiredness]], [[headache]]s, a [[malaise|general feeling of illness]], [[nausea]], [[vomiting]], frequent daytime urination, [[Anorexia (symptom)|lack of appetite]], [[Pruritus|itchy skin]], and [[edema|leg swelling]].<ref name=\"nih\" />\n\n==Risk factors==\nThe incidence of diabetic nephropathy is higher in people with diabetes that have one or more of the following conditions:<ref name=\"nih\">{{Cite web|title = Diabetes and kidney disease: MedlinePlus Medical Encyclopedia|url = https://www.nlm.nih.gov/medlineplus/ency/article/000494.htm|website = www.nlm.nih.gov|access-date = 2015-06-27}}</ref>\n* Poor control of blood glucose\n* Uncontrolled [[Hypertension|high blood pressure]]\n* [[Type 1 diabetes mellitus]], with onset before age 20\n* Past or current [[Tobacco smoking|cigarette use]]\n* A family history of diabetic nephropathy\n\n==Pathophysiology==\n[[File:Physiology of Nephron.png|250px|thumb|right|Diagram showing the basic outline of nephron structure and function: diabetic nephropathy is associated with changes in the afferent and efferent arterioles, causing capillary hypertension; and damage to the glomerular capillaries of multiple causes, including mesangial matrix deposition]] \nThe pathophysiology of the glomerulus in DN can best be understood by considering the three involved cells as a unit: the [[endothelial cell]], the [[podocyte]], and the [[mesangial cell]]. These cells are in physical contact with one another at various locations within the glomerulus; they also communicate with one another chemically at a distance. All three cells are abnormal in DN.<ref name=\"Schl\u00f6ndorff_2009\"/>\n\n[[Diabetes]] causes a number of changes to the body's [[metabolism]] and [[Hemodynamics|blood circulation]], which likely combine to produce excess [[reactive oxygen species]] (chemically reactive molecules containing oxygen). These changes damage the kidney's [[Glomerulus (kidney)|glomeruli]] (networks of [[Capillary|tiny blood vessels]]), which leads to the hallmark feature of [[albumin]] in the urine (called [[albuminuria]]).<ref>{{cite journal | vauthors = Cao Z, Cooper ME | title = Pathogenesis of diabetic nephropathy | journal = Journal of Diabetes Investigation | volume = 2 | issue = 4 | pages = 243\u20137 | date = August 2011 | pmid = 24843491 | pmc = 4014960 | doi = 10.1111/j.2040-1124.2011.00131.x }}</ref> As diabetic nephropathy progresses, a structure in the glomeruli known as the glomerular filtration barrier (GFB) is increasingly damaged.<ref name=\"Fernandez2014\"/> This barrier is composed of three layers including the fenestrated [[endothelium]], the [[glomerular basement membrane]], and the [[epithelium|epithelial]] [[podocyte]]s.<ref name=\"Fernandez2014\"/> The GFB is responsible for the highly selective filtration of blood entering the kidney's glomeruli and normally only allows the passage of water, small molecules, and very small proteins (albumin does not pass through the intact GFB).<ref name=\"Fernandez2014\"/> Damage to the glomerular basement membrane allows proteins in the blood to leak through, leading to proteinuria. Deposition of abnormally large amounts of mesangial matrix causes [[Periodic acid\u2013Schiff stain|periodic-acid schiff]] positive nodules called Kimmelstiel\u2013Wilson nodules.<ref>{{cite journal|author=Kimmelstiel, Paul|authorlink=Paul Kimmelstiel|author2=Wilson, Clifford|authorlink2=Clifford Wilson|title=Intercapillary lesions in the glomeruli of the kidney|journal=The American Journal of Pathology|volume=12|issue=1|year=1936|pages=83\u201398.7|pmc=1911022|pmid=19970254}}</ref>\n\n[[Hyperglycemia|High blood sugar]], which leads to formation of [[advanced glycation end product]]s;  and [[cytokine]]s have also been implicated as mechanisms for the development of diabetic nephropathy.<ref>{{Cite journal|title = Diabetic Nephropathy: Background, Pathophysiology, Etiology|url = http://emedicine.medscape.com/article/238946-overview#a4|date = 2015-06-20}}</ref>\n\n==Diagnosis==\n[[File:Ultrasonography of kidney with diabetic nephropathy - annotated.jpg|thumb|left|[[Medical ultrasonography|Ultrasonography]] showing [[Echogenicity|hyperechogenicity]] of the [[renal cortex]], visualized in the image as brighter than the liver.]]\n{| class=\"wikitable\" style=\"float:right; margin-left:5px\"\nDiagnosis is based on the measurement of abnormal levels of urinary albumin in a diabetic<ref name=\"lewis2014\">{{cite journal | vauthors = Lewis G, Maxwell AP | title = Risk factor control is key in diabetic nephropathy | journal = The Practitioner | volume = 258 | issue = 1768 | pages = 13\u20137, 2 | date = February 2014 | pmid = 24689163 }}</ref>  coupled with exclusion of other causes of albuminuria.\nAlbumin measurements are defined as follows:<ref>{{Cite web|title = CDC \u2013 Chronic Kidney Disease \u2013 Glossary|url = http://nccd.cdc.gov/ckd/help.aspx?section=G|access-date = 2015-07-02}}</ref> \n:::::::::::* Normal [[albuminuria]]: urinary albumin excretion <30&nbsp;mg/24h;\n:::::::::::* [[Microalbuminuria]]: urinary albumin excretion in the range of 30\u2013299&nbsp;mg/24h;\n:::::::::::* [[Macroalbuminuria]]: urinary albumin excretion \u2265300&nbsp;mg/24h.\nIt is recommended that diabetics have their albumin levels checked annually, beginning immediately after a diagnosis of type 2 diabetes and five years after a diagnosis of type 1 diabetes.<ref name=\"lewis2014\" /><ref>{{cite journal | vauthors = Koroshi A | title = Microalbuminuria, is it so important? | journal = Hippokratia | volume = 11 | issue = 3 | pages = 105\u20137 | date = July 2007 | pmid = 19582202 | pmc = 2658722 }}</ref>\n\n[[Medical imaging]] of the kidneys, generally by [[medical ultrasonography|ultrasonography]], is recommended as part of a [[differential diagnosis]] if there is suspicion of [[urinary tract obstruction]], [[urinary tract infection]], or [[kidney stone]]s or [[polycystic kidney disease]].<ref name=\"Grossde Azevedo2004\">{{cite journal | vauthors = Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T | title = Diabetic nephropathy: diagnosis, prevention, and treatment | journal = Diabetes Care | volume = 28 | issue = 1 | pages = 164\u201376 | date = January 2005 | pmid = 15616252 | doi = 10.2337/diacare.28.1.164 }}</ref>\n\n!CKD Stage<ref name=\"pmid22439155\">{{cite book | vauthors = Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ | display-authors = 6 | title = Chronic Kidney Disease Stages 1\u20133: Screening, Monitoring, and Treatment [Internet] | pmid = 22439155 | doi = | url = https://www.ncbi.nlm.nih.gov/books/NBK84558/ | publisher = Agency for Healthcare Research and Quality (US) | date = January 2012 }}</ref>\n\n!eGFR level <small>(mL/min/1.73 m<sup>2</sup>)</small>\n|-\n|Stage 1\n|style=\"text-align:center\"|\u2265 90\n|-\n|Stage 2\n|style=\"text-align:center\"|60\u201389\n|-\n|Stage 3\n|style=\"text-align:center\"|30\u201359\n|-\n|Stage 4\n|style=\"text-align:center\"|15\u201329\n|-\n|Stage 5\n|style=\"text-align:center\"|< 15\n|}\n===Staging===\nTo stage the degree of damage in this (and any) kidney disease, the serum creatinine is determined and used to calculate the estimated glomerular filtration rate ([[Estimated Glomerular Filtration Rate|eGFR]]). Normal eGFR is equal to or greater than 90ml/min/1.73 m<sup>2</sup>.<ref>{{Cite web|title = Glomerular filtration rate: MedlinePlus Medical Encyclopedia|url =  https://www.nlm.nih.gov/medlineplus/ency/article/007305.htm|website = www.nlm.nih.gov|access-date = 2015-07-02}}</ref>\n<br>\n<br>\n\n== Treatment ==\nThe goals of treatment are to slow the progression of kidney damage and control related complications. The main treatment, once proteinuria is established, is [[ACE inhibitor]] medications, which usually reduce proteinuria levels and slow the progression of diabetic nephropathy.<ref name=\"ace\">{{cite journal | vauthors = Lim AK | title = Diabetic nephropathy \u2013 complications and treatment | journal = [[International Journal of Nephrology and Renovascular Disease]] | volume = 7 | pages = 361\u201381 | date = 2014 | pmid = 25342915 | pmc = 4206379 | doi = 10.2147/IJNRD.S40172 }}</ref> Other issues that are important in the management of this condition include control of [[high blood pressure]] and [[blood sugar]] levels (see [[diabetes management]]), as well as the reduction of dietary salt intake.<ref>{{Cite journal|title = Diabetic Nephropathy Treatment & Management: Approach Considerations, Glycemic Control, Management of Hypertension|url = http://emedicine.medscape.com/article/238946-treatment|date = 2015-06-20}}</ref>\n\n==Prognosis==\nDiabetic nephropathy in type 2 diabetes can be more difficult to predict because the onset of diabetes is not usually well established. Without intervention, 20\u201340 percent of patients with type 2 diabetes/microalbuminuria, will evolve to macroalbuminuria.<ref>{{Cite journal|title = Clinical Evidence Handbook: Diabetic Nephropathy: Preventing Progression \u2013 American Family Physician|issue = 6|pages = 732|url = http://www.aafp.org/afp/2011/0315/p732.html|journal = American Family Physician|volume = 83|access-date = 2015-06-27|first = Michael|last = Shlipak | name-list-format = vanc |date = 2011-03-15}}</ref>\n\nDiabetic nephropathy is the most common cause of [[end-stage kidney disease]],<ref name=\"Fernandez2014\"/><ref name=\"Ding2015\"/> which may require [[hemodialysis]] or even [[kidney transplantation]].<ref name=\"ReferenceB\"/> It is associated with an increased [[Mortality rate|risk of death]] in general, particularly from [[cardiovascular disease]].<ref name=\"Fernandez2014\"/><ref name=\"P\u00e1lsson R 2014\"/>\n\n== Epidemiology ==\nIn the U.S., diabetic nephropathy affected an estimated 6.9 million people during 2005\u20132008.<ref>{{Cite book|title = Diabetes and Kidney Disease|url = https://books.google.com/books?id=wsYkBAAAQBAJ&pg=PA10&dq=Diabetic+nephropathy+epidemiology |publisher = Springer|date = 2014-01-01|isbn = 9781493907939 |first = Edgar V.|last = Lerma | name-list-format = vanc }}</ref> The number of people with diabetes and consequently diabetic nephropathy is expected to rise substantially by the year 2050.<ref>{{Cite book|title = Diabetes and the Kidney|url = https://books.google.com/books?id=XZk7AQAAQBAJ&pg=PA1&dq=Diabetic+nephropathy+epidemiology |publisher = Karger Medical and Scientific Publishers|date = 2011-06-08|isbn = 9783805597432 | vauthors = Lai KN, Tang SC }}</ref>\n\n== See also ==\n* [[Diabetic diet]]\n* [[Hyperbaric medicine]]\n* [[Nephrology]]\n\n== References ==\n{{Reflist|32em}}\n\n== Further reading ==\n{{refbegin|32em}}\n*{{Cite web|title = Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis|url = http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?AccessionNumber=12009100199#.VZXF8TfbJpg|website = www.crd.york.ac.uk|access-date = 2015-07-02}}\n* {{cite journal | vauthors = Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T | title = Diabetic nephropathy: diagnosis, prevention, and treatment | journal = Diabetes Care | volume = 28 | issue = 1 | pages = 164\u201376 | date = January 2005 | pmid = 15616252 | doi = 10.2337/diacare.28.1.164 }}\n* {{cite journal | vauthors = Tziomalos K, Athyros VG | title = Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis | journal = The Review of Diabetic Studies | volume = 12 | issue = 1\u20132 | pages = 110\u20138 | year = 2015 | pmid = 26676664 | pmc = 5397986 | doi = 10.1900/RDS.2015.12.110 }}\n* {{cite journal | vauthors = Kume S, Koya D, Uzu T, Maegawa H | title = Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy | journal = BioMed Research International | volume = 2014 | pages = 315494 | date = 2014 | pmid = 25126552 | pmc = 4122096 | doi = 10.1155/2014/315494 }}\n* {{cite journal | vauthors = Doshi SM, Friedman AN | title = Diagnosis and Management of Type 2 Diabetic Kidney Disease | journal = Clinical Journal of the American Society of Nephrology | volume = 12 | issue = 8 | pages = 1366\u20131373 | date = August 2017 | pmid = 28280116 | pmc = 5544517 | doi = 10.2215/CJN.11111016  }}\n{{refend}}\n\n== External links ==\n{{Medical resources\n|  DiseasesDB      =  \n|  ICD10           = E10.2, E11.2, E12.2, E13.2, E14.2\n|  ICD9            = {{ICD9|250.4}}\n|  ICDO            =  \n|  OMIM            =  \n|  MedlinePlus     = 000494 \n|  eMedicineSubj   =  \n|  eMedicineTopic  =  \n|  MeshID          = D003928 \n}}\n{{Scholia|topic}}\n{{Nephrology}}\n{{Endocrine pathology}}\n{{Diabetes}}\n\n{{Authority control}}\n\n{{DEFAULTSORT:Diabetic Nephropathy}}\n[[Category:Kidney diseases]]\n[[Category:Vascular diseases]]\n[[Category:Diabetes]]\n", "name_user": "Sherifkhafagy", "label": "unsafe", "comment": "", "url_page": "//en.wikipedia.org/wiki/Diabetic_nephropathy"}
